Risk factors for recurrence after intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity.
10.7499/j.issn.1008-8830.2205011
- Author:
Qing-Fei HAO
1
;
Jing CHEN
1
;
Peng RUAN
1
;
Gao-Pan LI
1
;
Jing ZHANG
1
;
Hao-Ming CHEN
1
;
Hong-Xiang GUO
1
;
Xiao-Juan SUN
1
;
Xiu-Yong CHENG
1
Author Information
1. Department of Neonatology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Anti-vascular endothelial growth factor;
Preterm infant;
Recurrence;
Retinopathy of prematurity
- MeSH:
Female;
Humans;
Infant;
Infant, Newborn;
Pregnancy;
Angiogenesis Inhibitors/therapeutic use*;
Endothelial Growth Factors/therapeutic use*;
Hemorrhage;
Hypertension, Pregnancy-Induced;
Oxygen/therapeutic use*;
Retinopathy of Prematurity/drug therapy*;
Retrospective Studies;
Risk Factors;
Vascular Endothelial Growth Factor A
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(11):1207-1212
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in the treatment of retinopathy of prematurity (ROP) and the risk factors for recurrence.
METHODS:A retrospective analysis was performed on the medical data of 159 infants with ROP who were born in the First Affiliated Hospital of Zhengzhou University and underwent anti-VEGF treatment from January 2016 to December 2021. According to the presence or absence of recurrence within the follow-up period after initial anti-VEGF treatment, they were divided into a recurrence group with 24 infants and a non-recurrence group with 135 infants. The medical data were compared between the two groups, and a multivariate logistic regression analysis was used to investigate the risk factors for the recurrence of ROP after anti-VEGF treatment.
RESULTS:After one-time anti-VEGF treatment, all 159 infants showed regression of plus disease. Recurrence was observed in 24 infants (15.1%) after anti-VEGF treatment, with a mean interval of (8.4±2.6) weeks from treatment to recurrence. The multivariate logistic regression analysis showed that preoperative fundus hemorrhage and prolonged total oxygen supply time were risk factors for the recurrence of ROP (P<0.05), while gestational hypertension was a protective factor (P<0.05).
CONCLUSIONS:Intravitreal anti-VEGF injection is effective for ROP. Preoperative fundus hemorrhage and long duration of oxygen therapy may increase the risk of ROP recurrence, and further studies are needed to investigate the influence of gestational hypertension on the recurrence of ROP.
